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1. Introduction  
Solubility of a drug is one of its important physico-chemical properties. More attention has 
been paid to the aqueous solubility since water is the unique solvent of biological systems. It 
is obvious that a drug should be reached to its receptors in the body through the aqueous 
and non-aqueous media. The chance of a low water soluble drug to be appeared in the 
market place is very low and nearly 40 % of the drug candidates fail to reach higher phases 
of the drug trials simply because of their low water solubility. The solubility in non-aqueous 
solvents is not too important from clinical viewpoint however these solubilities play curious 
roles in drug discovery and development investigations. Most of drugs are synthesized in 
non-aqueous media and/or extracted from natural sources using non-aqueous extracting 
solvents. Different polymorphs of some drugs could be produced from their crystallization 
using organic solvents. 
There are various methods for solubility determination of drugs which is discussed in this 
chapter. The experimental determination is tedious and time-consuming process and 
sometimes there is restrictions in the availability of enough amount of a drug candidate to 
be used in the solubility measurements, especially in the early stages of drug discovery 
investigations in which only small amount of a drug is synthesized/extracted and large 
number of preliminary biological tests should be carried out. To cover this limitation, and in 
order to provide a faster and easier tool, mathematical models have been developed to 
correlate/predict the solubility of drugs. These models are discussed in this chapter to 
provide an overall view for a pharmaceutical scientist who is working in the research and 
development department of a company and/or a research laboratory within academia. In 
addition to the accurate calculations which are expected from these models, the simplicity of 
the required computations is another parameter which should be taken into account, since 
more complex computations did not attract more attention in the pharmaceutical industry. 
1.1 Solubility and dissolution 
When talking about solubility, there are two concepts which might be confused with each 
other: solubility and dissolution. The term solution (i.e. thermodynamic solution) is used to 
define the state which is thermodynamically stable and shows the neat result of an 
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equilibrium between a solute (the compound which is going to be dispersed molecularly in 
another medium which is called solvent) and its dissolved form in the medium. The 
dissolving process is the migration of the molecules of the solute to the solvent medium and 
makes the solution which after reaching a steady state is called homogenous solution and 
can be represented by the following equilibrium: 
 
 
 
 Solid LiquidX Y Concenteration   
How much a solute is molecularly dispersed in the solvent is called solubility and the rate of 
dissolving is called dissolution. Hence, the solubility value is a thermodynamic property while 
the dissolution rate is a kinetic one. In other words, time has no effect on solubility value and is 
not important in its related subjects, but it is important in dissolution related subjects. 
The solubility is important in stable forms including liquid formulations and dissolution is 
important in transient states including the release of the drug from its formulation to 
biological fluids and permeability (Sinko and Martin, 2006). In pharmaceutical sciences, 
especially in formulation, designing a stable liquid formulation requires the knowledge on 
the solubility value and an effective drug delivery to the body mostly depends on the 
dissolution rate which is affected by the solubility (Allen et al., 2006). However, they both 
affect each other based on Noyes-Whitney equation (Sinko and Martin, 2006): 
 
 SDA C CdW
dt L
  (1) 
where dW/dt is the rate of dissolution, A is the surface area of the solid which is in direct 
contact with the molecules of the solvents, C is the concentration of the solute in the medium 
(dissolved amount), CS is the concentration of the solute in the diffusion layer, D is the 
diffusion coefficient, and L is the thickness of the diffusion layer. 
Based on the discussed topics, solubility and dissolution are in relation with each other, but 
not the same. So, they must not be used in place of each other as the consequences can be 
awful! For example, a drug substance might be highly soluble, but dissolves slowly (or vice 
versa). So, in the formulation of such compounds, the difference between solubility and 
dissolution must be considered. 
1.2 Solubility of base form of drugs 
The apparent solubility ( AppS ) of a weak electrolyte is expressed by: 
 App M IS S S   (2) 
in which MS  is the molecular form of the drug and IS  is the ionized form of the drug in the 
solution. For strong electrolytes, IS  is predominant whereas for nonelectrolytes MS  is the 
Solvent molecules 
Solute molecules 
Solution 
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only form of the solubilized drug in the solution. MS  is also called intrinsic solubility or 0S . In 
early stages of drug discovery, only small amount of the new drug is available and its purity is 
not assured. In this stage, the solubility determination in acidic and/or basic solutions could be 
used in practice. Increased apparent solubility in acidic or basic medium reveals that the new 
drug is a basic or an acidic solute. No increase in the solubility means that the drug is a 
nonelectrolyte. Increased solubility in both acidic and basic media indicates either zwitterionic 
or amphoteric behaviour. The intrinsic solubility of a drug could be determined from apparent 
solubility data at various pH values. When the purity of a drug candidate is not assured, a 
phase-solubility diagram, i.e. the solubility at different solute:solvent ratios, is recommended. 
In this diagram, the co-solute effect (self association, complexation, solubilization) increases the 
solubility and the common ion effect decreases the solubility and no change in the solubility 
might mean that drug is pure and no interaction exists. 
1.3 Solubility of salt form of drugs 
Salt formation of weak acidic or basic drugs is one of their solubility increasing methods 
since the ionized species have greater solubility in water and other polar solvents and a 
number of drugs are marketed as their salt forms. The most common salts used for salt 
formation of acidic drugs are sodium, potassium, calcium and zinc and those for basic drugs 
are hydrochloride, sulphate, mesylate, maleate, phosphate, tartrate, citrate and besylate 
(Wells, 1988). Different slats of a given drug possess various solubilities. As an example, the 
solubility of lamotrigine with the counterions of tartrate, saccharinate, succinate and 
fumarate are 2.63, 1.37, 0.61 and 0.43 millimole per liter (Galcera and Molins, 2009). The 
selection of the salt of a drug is mainly carried out by trial and error basis considering 
practical issues such as cost of raw materials, ease of crystallization, percent yield, thermal 
stability and hygroscopicity of the resulting salt. Black et al. (2007) investigated the salt 
formation of 17 salt forms of ephedrine and reported their physicochemical properties and 
tried to develop a relationship between these properties which was not successful. Any 
model representing the properties of salt forms of drugs is a highly in demand subject in the 
pharmaceutical industry. As an example, the relation between the dielectric constant of the 
solvent and the solubility of drugs in their salt form, can be mentioned (Fakhree et al., 2010). 
1.4 Solubility of pharmaceutical macromolecules 
Polymers and macromolecules are important parts of drug design and development. The 
emerging technology of proteins, peptides, DNA and RNA sequences as pharmaceutical 
active ingredients makes it necessary for consideration of their physicochemical properties 
in pharmaceutical sciences, including solubility. For the beginning, in terms of 
macromolecules, it is better to use dispersion versus solubility in a medium and this makes 
a difference between their solubility in comparison with small organic molecules. The 
dispersion of the macromolecules in the solution results in formation of new properties for 
the solution such as increase in viscosity, light scattering, molecular network formation (e.g. 
gel) etc (Sinko and Martin, 2006). Another important note about macromolecules, is the fact 
that they have been produced in an aqueous medium and have philia to watery media (not 
always, but in most of the cases). Hence, they are sensitive to presence of organic solvents 
and might be precipitated by addition of the organic solvents (unlike small organic 
nonelectrolyte molecules which dissolve in organic media more than aqueous solutions). 
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The solubility of proteins is influenced by the ratio of the hydrophobic and hydrophilic 
residues of amino acids and their arrangement in the final structure of the protein (Bolen, 
2004). For example, globular proteins have hydrophobic residues in their core and 
hydrophilic residues in their surface. It is also affected by the pH and ionic strength of the 
water, presence of organic solvents and other polymers (Burgess, 2009). When talking about 
the solubility of proteins, there are different kinds of low solubility for the proteins: 
1. in-vitro low solubility due to structural properties of the protein (hydrophobic 
residues), 
2. in-vivo low solubility due to over expression of the protein in an organism (E. coli), 
3. amyloid formation which results in aggregation of the proteins because of their 
hydrophobic, residue charge, and ǃ-sheets in the structure, and 
4. low solubility due to conformational changes (Trevino et al., 2008). 
For increasing a protein’s aqueous solubility, one of the strategies is addition of additives 
such as L-arginine and L-glutamic acids. Fusion of peptides and proteins is another method 
which is addition of a solubilizing sequence of amino acids or protein to the structure of the 
low soluble protein. Mutation in the hydrophobic amino acids sequences to hydrophilic 
ones is another strategy. However, this might not work in all of the cases (Trevino et al., 
2008). Another approach is screening to find a more soluble homologue of that protein in 
other organisms (Waldo, 2003). 
1.5 Solubility of drugs in biological fluids 
For understanding the dissolution of a drug in the human body fluids, it is crucial to focus 
on the solubility of drugs in more realistic environment and to acquire larger amount of 
experimental data for simulating the solubility at different pHs, in the presence of bile salts 
etc which exists in the real solubilization media within human body. Solubility data of drugs 
in biorelevant media are increasingly required in early phases of drug discovery to predict 
the bioavailability of a drug after oral administration.  
1.6 Solubility modifications 
Solubility modification of drugs is required in separation, purification, analysis and 
formulation investigations and different methods are used to achieve the 
increased/decreased solubility values. 
1.6.1 Solubility increasing 
Several methods have been used to enhance the aqueous solubility of drugs including 
cosolvency, hydrotropism, complexation, ionisation, use of the surface active agents, crystal 
structure modifications and addition of ionic liquids. These methods have been discussed in 
details in the literature (Myrdal and Yalkowsky, 1998). Mixing a permissible non-toxic 
organic solvent with water, i.e. cosolvency, is the most common and feasible technique to 
enhance the aqueous solubility of drugs. The common cosolvents which, are used in the 
pharmaceutical industry are ethanol, propylene glycol, glycerine, glycofural, polyethylene 
glycols (mainly 200, 300 and 400), N,N-dimethyl acetamide, dimethyl sulfoxide, 2-propanol, 
dimethyl isosorbide, N-methyl 2-pyrrolidone (NMP) and room temperature ionic liquids 
(Rubino, 1990; Mizucci et al., 2008; Jouyban et al., 2010a). Their applications and possible 
side effects have been discussed in the literature (Spiegel and Noseworthy, 1963; Tsai et al., 
1986; Patel et al., 1986; Golightly et al., 1988; Rubino, 1990). Hydrotropes are a class of 
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amphiphilic molecules that cannot form organized structures, such as micelles, in water but 
they increase the aqueous solubility of drugs. Often strong synergistic effects are observed 
when hydrotropes are added to aqueous surfactant or polymer solutions. Caffeine and 
nicotinamide are well known hydrotropic agents and their ability to solubilize a wide 
variety of therapeutic drugs including riboflavin (Lim and Go, 2000) has been demonstrated. 
Complexation of drugs is another solubilization technique and there are a number of reports 
on complexation of drugs by cyclodextrins. Ionization is applicable for weak electrolytes 
and the solubility of some drugs could be increased by changing pH of the solution.  
1.6.2 Solubility decreasing 
In precipitation and crystallization processes as a part of extraction and purification of the 
pharmaceutically related compounds, lowering the solubility is desirable. Lowering the 
solubility for pharmaceutical compounds might include using of temperature alteration, 
addition of antisolvent, using of a low soluble salt or ester of the drug, and producing low 
soluble polymorphs (Blagden et al., 2007; Widenski et al., 2009). 
Precipitation or crystallization both can be used in this regard depending on the rate of 
solubility decreasing. If it is happened quickly, then the solid state might be in 
amorphous form and the process called precipitation. If the lowering of solubility takes 
place in a controlled way that crystal growth can happen, then the process called 
crystallization. Precipitation of proteins and macromolecules such as DNA and RNA are 
other examples for this kind of solubility modification. In protein biosynthesis and 
extraction, different methods of desolubilization are used which include: salting out, 
isoelectric point precipitation, precipitation with organic solvents, addition of non-ionic 
hydrophilic polymers, flocculation by polyelectrolytes, and addition of polyvalent 
metallic ions (Burgess, 2009). Another reason making it desirable to precipitate 
macromolecules such as proteins, DNA, and RNA is pre-treatment of biological analytes 
before starting analyses. 
Recrystallization is another process which is used in pharmaceutical sciences and means to 
dissolve a compound in a medium, and by modifying the physicochemical conditions made 
the dissolved compound to crystallize again. This technique is widely used in crystal 
engineering technology which can produce amorphous, different polymorphs, and 
psudopolymorphs of a drug (Blagden et al., 2007). This is important in modification of 
pharmaceutically interested physicochemical properties such as compressibility in 
formulation process, size of particles, dissolution rate, as well as solubility (Allen et al., 2006; 
Gibaldi et al., 2007). 
The above mentioned processes are related to preformulation processes. In formulation of 
pharmaceutical active ingredients the desire for lowering solubility can be seen in designing 
of sustained release and depot dosage forms or drug delivery systems (Allen et al., 2006; 
Gibaldi et al., 2007). For making a sustained release dosage form of a drug, different 
formulation techniques such as use of polymeric matrix, osmotic pumps, and crystallization 
of a poorly water soluble compound are used. For designing a depot drug delivery system, 
possible solutions include: use of low soluble salts or esters of a drug (e.g. 
methylprednisolone acetate), addition of additives (e.g. zinc and insulin), very concentrated 
non-aqueous solutions of drug (e.g. Leuprolide and NMP), and depot dosage forms (e.g. 
implants of low soluble compounds such as sex hormones) (Strickley, 2004; Allen et al., 
2006; Gibaldi et al., 2007). 
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Also low solubility is useful when stability of a pharmaceutical compound is low in its 
solubilized form (Sinko and Martin, 2006). Hence, suspension formulations (i.e. ready to use 
and lyophilized powder for suspension preparation) might be a useful strategy. 
In the recent decade, emerging technologies such as micro-formulation, micro-
encapsulation, nano-formulation, and nano-encapsulation are using solubility decreasing 
principals as a part of their processes. This is usually done by addition of antisolvent and 
fine particle stabilizers to gain a suspension with micro/nano-sized particles. 
2. Experimental methods for determination of solubility 
The solubility of a drug could be measured experimentally using two procedures, namely 
the thermodynamic and kinetic solubility methods. The thermodynamic solubility 
determination methods are not feasible at the early discovery stage because of the large 
sample requirement, low throughput and laborious sample preparation. The kinetic 
solubility determinations could be used as an alternative method at this stage. 
2.1 Determination of thermodynamic solubility 
Solubility determination of drugs in a liquid could be classified as analytical and synthetic 
methods. The main advantage of the analytical (shake flask) method is the possibility of 
measuring a large number of samples simultaneously however this method is tedious and 
time-consuming.  
2.1.1 Shake flask method 
The shake-flask method of Higuchi and Connors (1965) is the most reliable method for low 
soluble compounds and widely used solubility measurement method. In this method, an 
excess amount of drug is added to the solubility medium. The added amount should be 
enough to make a saturated solution in equilibrium with the solid phase. In case of acidic or 
basic drugs dissolved in an un-buffered solubility medium, further addition of the solid 
could change pH of the solution and consequently the solubility of the drug (Wang et al., 
2002; Kawakami et al., 2005; Jouyban and Soltanpour, 2010). Depending on the dissolution 
rate and type of agitation used, the equilibration time between the dissolved drug and the 
excess solid could be varied. Equilibration is often achieved within 24 hours. To ensure the 
equilibration condition, the dissolution profile of drug should be investigated. The shortest 
time needed for reaching the plateau of drug concentration against time could be considered 
as a suitable equilibration time. Any significant variation on dissolution profile after 
reaching the equilibration should be inspected, since there are a number of possibilities 
including degradation of the drug and also its polymorphic transformation. Both these 
affect the solubility values of a drug dissolved in the dissolution media. Heating, vortexing 
or sonicating the sample prior to equilibration could shorten the equilibration time. To 
overcome the poor wettability of low soluble drugs, one may use small glass microspheres 
or sonication. Then the two phases, solid and solution phases, are separated using two 
common methods of filtration and/or centrifugation. Filteration is the easiest method, 
however, the possible sorption of the solute on the filter should be considered as a source of 
error in solubility determination, especially for very low soluble drugs. Pre-rinsing the filter 
with the saturated solution could reduce the sorption of the solute on the filter by saturating 
the adsorption sites. Centrifugation or ultra-centrifugation is preferred in some cases, and 
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the higher viscosity of the saturated solutions, e.g. in mixed solvents, should be kept in 
mind as a limitation. A combination of filtration and centrifugation is also could be used. 
The UV spectrophotometric analysis is the most common and the easiest analytical method. 
The next is the HPLC methods both in isocratic and gradient elution modes. The HPLC 
analysis could also detect the possible impurities or degradation products if a highly 
selective method was used. X-ray diffraction (XRD) and differential scanning calorimetry 
(DSC) of the residual solid separated from the saturated solution confirm the possible solid 
phase transformations during equilibration.  
2.1.2 Synthetic method 
The synthetic method (Hankinson and Thompson, 1965; Ren et al., 2005; Yang et al., 2008; 
Yu et al., 2009) which is so called laser monitoring technique (Li et al., 2006), last crystal 
disappearance method (Hao et al., 2005) and dynamic method (Peisheng and Qing, 2001; 
Weiwei et al., 2007; Wang et al., 2008) is based on disappearance of the solid drug (from 
the mixture of solvent and drug) monitored by a laser beam. The history of this method 
backs to 1886 and first introduced by Alexejew and then modified by other research 
groups (Ward, 1926). The disappearance of drugs could be achieved either by changing 
the temperature or by addition of a known amount of the solvent. It is claimed that the 
synthetic method is much faster and more reliable than analytical method (Yang et al., 
2008). Figure 1 illustrates a schematic representation of the most completed set up used in 
the synthetic method. 
 
 
Fig. 1. Schematic representation of the synthetic method for determination of solubility of 
drugs; 1, magnetic stirrer; 2, laser generator; 3, jacketed glass vessel; 4, condenser pipe; 5, 
thermometer; 6, thermocouple; 7, rotor; 8, photoelectric transducer; 9, controller; 10, laser 
strength display; 11, constant temperature bath; 12, workstation. (Figure is reproduced from 
Ren et al., 2005). 
The solubility apparatus consisted of a jacketed glass vessel (varying from 60 to 250 mL) 
maintained at the desired temperature by circulating water that was provided by a constant-
temperature bath. The water temperature was controlled by a workstation with a 
temperature accuracy of (0.1 K) achieved continuous stirring, and a condenser (or a 
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perforated rubber cover) was fitted to reduce the solvent’s evaporation. A thermometer with 
an uncertainty of 0.01 K was used to determine the temperature of the system. A laser beam 
was used as a tool to observe dissolving the solid in liquid. The signal transmitted through 
the vessel was collected by a detector that decided the rate of temperature rise and 
estimated the equilibrium point of the given system on the basis of the signal change. The 
solute and the solvent were prepared using an electronic balance with the estimated 
uncertainty in the mole fraction of less than 0.001. A predetermined quantity of drug and 
solvent was placed into the jacketed vessel. The system was slowly heated (heating rate 
increase is 0.5 to 2 K·hr-1) with continuous stirring. When the solute particles disappeared 
thoroughly, the signal approached a maximum value. The workstation judged the signal 
difference at 10-min intervals; if the interval was less than 10, then the workstation gave an 
order to stop heating and record the temperature. The temperature recorded was the liquid 
temperature of a given composition upon the complete dissolution of the drug (Ren et al., 
2005). In another version of this set up, predetermined masses of drug and solvent were 
placed in the vessel and the contents were stirred continuously at a constant temperature. 
As the particles of the drug are dissolved, the intensity of the laser beam increased gradually 
and reaches to the maximum value when the drug is dissolved completely. Then an 
additional known mass of the drug is introduced to the vessel and the procedure is repeated 
until the laser beam could not return to the maximum value which means the last addition 
could not be dissolved. The total amount of the added drug is recorded and used to 
calculate the solubility value (Yang et al., 2008). The synthetic method is preferred over 
shake flask method for solubility determination of drugs in viscous solvents where 
separation of the excess solids from saturated solutions is not achievable (Grant and 
Abougela, 1983). 
2.2 Determination of kinetic solubility 
In drug discovery and development, one of the rationalized methods is high-throughput 
screening (HTS) which includes the design and synthesis of a large set(s) of chemicals to 
find hit compounds based on specific physicochemical properties (PCPs) and to develop 
lead compound. One of the important PCPs in determination of hit and lead compounds is 
aqueous solubility (Pan et al., 2001; Alsenz and Kansy, 2007; Hoelke et al. 2009). However, in 
practice it is not possible to experimentally determine thermodynamic solubility value in 
HTS approaches. This is because of large number of compounds which might be more than 
1000 compounds in each HTS experiment or little amount of synthesized compounds which 
is around a few milligrams and is another limiting factor (Pan et al., 2001; Alsenz and Kansy, 
2007; Hoelke et al. 2009). 
Kinetic solubility determination methods were used for covering this problem. The 
advantages of the kinetics solubility determination in comparison with thermodynamic 
solubility determination methods are capability to being easily automated, accuracy, 
rapidity and requiring less amount of the solute (Pan et al., 2001; Alsenz and Kansy, 2007; 
Hoelke et al. 2009). Its disadvantages might include not assessing the crystal effect on the 
solubility, the cosolvent action of the dimethyl sulfoxide (DMSO), and its applicability is 
good for compounds which have solubility more than 10-6 molar. Some of the well 
established approaches include: nephelometric, UV-Spectroscopic, and HPLC methods 
which are discussed in the following. 
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2.2.1 Nephelometric method 
The nephelometry is based on turbidimetry. Figure 2 shows a schematic view of the 
mechanism of turbidimetry. For sample preparation in this method, a 10 millimolar 
concentration of a solute was prepared by dissolving suitable amounts of the solute in 
DMSO. Then, this stock solution is used to prepare sample solutions in the range of 5  10-7 
to 5  10-4 molar. For concentrations above the 10-4 molar, the solutions prepared by direct 
dilution of the stock solution and for the lower concentrations, serial dilutions were used 
where the dilutant is a buffer. These dilutions are directly take place in a 96-well plate with 
the total 5% concentration of DMSO and the final volume of ≈200 μL (Pan et al., 2001; 
Hoelke et al. 2009). This optimum volume is based on the fact that light scattering (for a 
specific condition) is nearly constant for a range of particle sizes (Pan et al., 2001) which 
make the process reproducible and accurate. 
For sample analyzing after the preparation section, the 96-well plate is placed in a 
nephelometer apparatus for measurement of the light scattering. It uses a laser beam (with a 
fixed wavelength in the range of 550-750 nm) as the light source, and a detector which is 
placed with a specific angle to the light source. Based on plotting turbidity against prepared 
concentrations, and drawing its asymptotes and finding their meeting point x coordination, 
gives the kinetic solubility (see Figure 3) (Pan et al., 2001; Hoelke et al. 2009). 
With this method, the kinetic solubility for a plate of 96 samples can be measured in a few 
minutes. 
2.2.2 UV/Vis-spectroscopic method 
There are two methods using UV/Vis-spectroscopy for kinetic solubility determination: 
Method 1 is based on turbidimetry and the other is based on light absorbance intensity as a 
function of concentration (Pan et al., 2001). 
 
 
Fig. 2. Schematic representation of turbidimetry. 
2.2.2.1 UV/Vis-spectroscopic method 1 
The sample preparation is like nephelometry method, but the analyzing is with a 96-well 
plate UV/Vis-spectroscopy apparatus. This provides a wider range of wavelength to choose 
for reading the samples turbidity (190-1000 nm) (Pan et al., 2001). The lower the wavelength, 
the smaller particle is detected. However, in practice, wavelengths greater than 500 nm is 
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used. This is because of the fact that most of organic compounds which have UV absorbance 
(e.g. contain a benzene ring) also have fluorescence property and might interfere with 
turbidimetry which reads the amount of reflected light (or fluorescence emission light) (Pan 
et al., 2001). An example of this is phenol red which has light absorption in 430 and 560 nm 
and is exited by these wavelengths which results in fluorescence emission (Pan et al., 2001). 
Another limitation is the UV absorbance of the most plates which are made of plastics (Pan 
et al., 2001). 
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Fig. 3. The method for finding kinetic solubility. 
2.2.2.2 UV/Vis-spectroscopic method 2 
In this method, sample dilution in range of 7  10-9 to 5  10-4 molar is performed. But after 
precipitation of the stock solution by the aqueous solution, the samples are filtered to 
another plate. And in this part, 20% acetonitrile is added to the filtered samples for 
prevention of solute precipitation during analysis. Then the plate is read with a 96-well plate 
UV/Vis-spectroscopy apparatus and the recorded data changed to molar concentration 
(determined by calibration curve obtained by standard solutions using another plate) (Pan 
et al., 2001; Hoelke et al. 2009). 
2.2.3 HPLC method 
The sample preparation for this method is the same as UV/Vis-spectroscopic method 2 and 
the transferring of samples to the 96-well plate is not required. However, filtration of 
samples is done prior to injection to the HPLC or online filtration is applied. A calibration 
curve is required for the determination of the concentrations of the prepared samples. This 
method is the most accurate one in comparison with other mentioned methods (limit of 
detection < 10-8 molar). But it must be considered that it consumes much more time (around 
6 hours for 96 samples) (Pan et al., 2001; Hoelke et al. 2009). A comparison between the 
mentioned methods is given in Table 1. 
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Method Calibration Specificity Easy Cut off LOD Rapidity 
Nephelometric Not required Low Yes No Low High 
UV/Vis 1 Not required Low Yes <500 nm Low High 
UV/Vis 2 Required Medium No <250 nm Medium Medium 
HPLC Required High No No High Low 
Table 1. The comparison between four kinetic solubility determination methods 
Kinetic solubility values are valuable source in early stage of drug discovery in place of 
thermodynamic solubility values where there is good correlation between trends of these two 
values for a set of compounds (Hoelke et al. 2009). However, because of the amorphic nature 
of the solutes, in most of the cases the kinetic solubility is higher than thermodynamic 
solubility values. The effect of 5% DMSO as a cosolvent on the solubility value in kinetic 
solubility determination methods also should be considered. This is very important where 
most of the drugs have very low aqueous solubility and very small amounts of solubilizing 
agents such as cosolvents (e.g. DMSO) enhance their solubility largely. 
Also the effect of time after dilution is important, especially in turbidimetry methods. 
Hoelke et al. have shown that by increasing the time after dilution and precipitation, the 
determined solubility become smaller (Hoelke et al. 2009). 
2.3 Data validation 
The collected data could be compared with the previously reported data in order to ensure 
the accuracy of the experimental procedure employed. Any mistake in the dilution steps, 
and miscalculations, or using un-calibrated instruments, such as un-calibrated balances, 
temperature variation and some other factors could be resulted in different solubility values 
for a given drug dissolved in a solvent at a fixed temperature. 
3. Computational methods for solubility prediction 
Computational methods in recent decades have become an important part of drug design 
and discovery. They are classified as theoretical, semi empirical and empirical equations. 
Most of models used in pharmaceutical sciences are semi-empirical (which is theoretical 
correlation of experimentally determined values) or empirical equations (which is 
mathematical correlation of experimentally determined values). Examples for semi-
empirical models are those correlations which use physicochemical parameters in their 
relationships. In other word, it is needed for them to be calculated based on experimental 
determinations at least for one time. For example in Noyes-Whitney equation, the diffusion 
coefficient must be determined at least for one time for a solute. So the Noyes-Whitney 
equation is a semi-empirical model. The quantitative structure property relationships 
(QSPR) and quantitative structure activity relationships (QSAR) are examples for empirical 
modelling. The pioneer for this type of equations in pharmaceutical sciences is Prof. Crowin 
H. Hansch. He has developed a QSPR model for solubility prediction of liquids, based on 
their partition coefficient (Hansch et al., 1968): 
 log 1.339log 0.978S P    (3) 
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where logP is the logarithm of the partition coefficient between octanol and water for a 
specific liquid. 
In another grouping, the correlation could be developed using linear modelling or non-
linear modelling. Linear modelling is the simple linear regression (or multiple linear 
regression) and non-linear modelling is artificial neural network, as examples. There are 
advantages and disadvantages for each type of modelling which is listed in the Table 2: 
 
Modelling 
type 
Advantages Disadvantages 
Linear 
- Simple to perform 
- Fast 
- Robust 
- Reproducible 
- Easy to use 
- The resulted model can be analyzed 
theoretically 
- Performable with small number of 
cases 
- It cannot analyze non-linear and 
complex behaviour 
- Most of the time the results have 
low accuracy 
Non-linear 
- Can analyze non-linear and complex 
behaviour 
- The results have high accuracy 
- Easily over fitting occurs 
- Many iterations are required 
- Need almost large number of cases 
- Reproducibility is hard 
- You must have the trained model 
to be able to predict new cases 
- It gives a black box instead of a 
model 
Table 2. Advantages and disadvantages of linear and non-linear modelling in QSPR studies 
In QSPR modelling, the variables used for correlation of physicochemical properties are 
called descriptors. These descriptors include simple structure derived parameters (e.g. 
number of carbon atoms, number of single bonds), overall structural parameters (e.g. 
molecular weight, and molecular volume), structure residues parameters (e.g. distance 
between two atoms, total charge on oxygen atoms), or physicochemical properties (e.g. 
melting point, partition coefficient). In solubility correlation almost all kinds of descriptors 
have been used. Around half of the models use logP as one of descriptors in modelling 
(Dearden, 2006). The following categories of descriptors have been used in solubility 
correlation: 
1. PCPs (such as melting point, molecular weight, molar refraction, …),  
2. structure related descriptors (such as molecular volume, solvent accessible surface area, 
number of rotatable/rigid bonds, number of hydrogen bond donor/acceptor atoms, …),  
3. quantum chemical descriptors (such as optimized total energy, HOMO and LUMO 
energies, …),  
4. topological parameters,  
5. molecular connectivity indices,  
6. electrostatic state (E-state) descriptors,  
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7. group contribution method or fragment based approach (different fragments derived 
rom structure, SMILIES/InChI codes),  
8. solvatochromic parameters (Dearden, 2006; Katritzky et al., 2010; Jouyban et al., 2010b).  
Other descriptors have been used as well, and a number of mixtures of the mentioned 
parameters are used, too. In the next section, the easiest and the most accurate models for 
solubility prediction are discussed. Also approaches like mobile order theory and 
differential equations of activity coefficient for the calculation of solubility have been used 
as semi-empirical methods (Dearden, 2006; Katritzky et al., 2010). 
For modelling, multiple linear regression (MLR), partial least square (PLS), support vector 
machine (SVM), artificial neural network (ANN), random forest (RF), Monte Carlo 
simulation (MCS), and other methods are used. Mostly, correlation coefficients of the non-
linear methods are better than linear methods and the related errors are smaller (Dearden, 
2006; Katritzky et al., 2010). This might suggest a nature of non-linear behaviour for 
solubility. 
3.1 Aqueous solubility 
Available models and software to predict the aqueous solubility of drugs were reviewed in 
a recent work (Jouyban et al., 2008). Solubility of drugs in water could be predicted using 
different models presented in the literature. The general single equation of Yalkowsky is the 
simplest and the most common method in the pharmaceutical area. The model requires 
experimental melting point (mp) and logarithm of partition coefficient (logP) as input data 
and is expressed as: 
 log 0.5 0.01( 25) logWS mp P     (4) 
where Sw is the molar aqueous solubility of a drug at 25 ºC. If the solute has a melting point 
less than 25 ºC, the (mp-25) term is set to zero (Ran et al., 2001). The two parameters, logP 
and mp are good representatives of effects of hydrophobicity and crystal packing on the 
solubility of a certain solute. Jain et al. (2008) provided some theoretical background for 
general single equation from thermodynamic principles. The simplicity of the model is its 
main advantage and a possible disadvantage is the melting point as an experimental 
parameter which may not be available for some of the compounds in early stages of drug 
discovery. An attempt has been made to predict the melting points from chemical structure 
was not successful (Jain and Yalkowsky, 2010) and it is recommended to use experimental 
values of melting point in the computations using general single equation (Chu and 
Yalkowsky, 2009). Also drugs with high melting points which decompose before melting are 
not suitable to be predicted by this model. The logP is measured using experimental 
methods such as HPLC, and/or calculated by some computational methods, then applied to 
solubility prediction.  
The linear solvation energy relationship is another model developed by Abraham and his 
co-workers (Stovall et al., 2005a) and is presented as: 
  log 0.395 0.955 0.320 1.155 3.255 0.785 3.330WS E S A B A B V         (5) 
in which E is excess molar refraction of the compound, S is dipolarity/polarizability, A and 
B are hydrogen bond acidity and basicity, respectively, which these later three parameter (S, 
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A and B) determined from solubility data of a compound in water and different organic 
solvents, the A B  term is a representative of hydrogen-bond interactions between acidic 
and basic functional groups of the drug in its pure solid or liquid, V is one percent of the 
McGowan volume and simply is calculated using group contribution method (Stovall et al., 
2005). 
In a recent work from our group, a simple equation was proposed to predict the aqueous 
solubility of drugs trained by the solubility data of pharmaceuticals (220 drugs) and  
was validated using various validation methods (Shayanfar et al, 2010). The proposed 
model is: 
 log 1.120 0.599 logWS E C P    (6) 
Both parameters (E and ClogP or computed logP) employed in equation 6 are computed 
using Pharma-Algorithms (Pharma Algorithms, 2008), therefore, the model is an in silico 
model and no experimental data is required in the prediction procedure. In the 
pharmaceutical literature, an external prediction set consisting of aqueous solubility of 21 
pharmaceutical and non-pharmaceutical compounds (Ran et al., 2001) usually were used to 
test the prediction capability of the proposed models. This data could not well represent the 
aqueous solubility data of pharmaceutical compounds, and another data set has been 
proposed consisting of the solubility of 75 official drugs collected from the literature. A list 
of the proposed test set and the experimental and predicted aqueous solubilities using 
equations 1-3 are listed in Table 3. 
 
Drug Experimental Equation 4 Equation 5 Equation 6 
Acetaminophen -1.06 -1.18 -0.63 -1.39 
Acetazolamide -2.49 -1.18 0.06 -1.43 
Acyclovir -2.24 -0.37 0.91 -1.26 
Allopurinol -2.26 -2.19 0.38 -1.30 
Amiloride -3.36 -1.96 -0.07 -2.74 
Amoxicilin -2.17 -0.11 -1.90 -2.38 
Antipyrine 0.39 -0.9 -1.16 -1.91 
Atenolol -1.30 -0.98 -1.85 -1.81 
Atropine -2.12 -1.77 -3.77 -2.43 
Azathioprine -3.21 -1.98 -1.95 -3.16 
Baclofen -1.67 -0.53 -1.84 -0.76 
Benzocaine -2.33 -1.98 -1.82 -2.14 
Celecoxib -3.74 -3.73 -5.38 -4.55 
Chloramphenicol -2.11 -1.57 -2.16 -2.55 
Chlorpromazine -5.27 -4.82 -5.97 -5.72 
Ciprofloxacin -3.73 -1.11 -2.78 -2.04 
Colchicine -0.96 -1.76 -3.93 -3.00 
Cortisone -3.00 -2.72 -4.43 -2.88 
Dapsone -3.19 -2.43 -2.05 -2.94 
Diazepam -3.76 -3.34 -4.58 -4.06 
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Diethylstilbestrol -4.57 -5.805 -4.94 -4.82 
Digoxin -4.16 -3.12 -10.31 -4.94 
Diltiazem -2.95 -4.39 -4.64 -4.41 
Ephedrine -0.47 -0.52 -1.28 -1.65 
Estradiol -4.84 -4.95 -4.53 -4.43 
Famotidine -2.48 -0.09 -1.18 -2.53 
Fluorouracil -1.03 -1.24 0.55 -0.38 
Gemfibrozil -3.16 -4.26 -4.44 -3.54 
Griseofulvin -4.61 -3.45 -3.47 -3.28 
Guaifenesin -0.60 -0.36 -1.10 -1.45 
Haloperidol -4.43 -4.08 -5.44 -4.22 
Halothane -1.71 -1.68 -1.99 -1.56 
Hydrochlorothiazide -2.63 -1.61 -1.04 -2.18 
Hydroquinone -0.18 -1.66 -0.23 -1.56 
Isoniazid 0.01 -0.154 0.97 -0.85 
Ketoprofen -3.25 -2.73 -3.95 -3.27 
Labetalol -3.45 -3.44 -4.32 -3.75 
Lamotrigine -3.14 -4.05 -3.48 -4.26 
Levodopa -1.72 -0.02 -0.35 -0.29 
Lindane -4.60 -4.08 -4.53 -3.76 
Lovastatin -6.01 -5.40 -6.42 -4.18 
Manitol 0.06 1.08 0.89 -0.18 
Maprotiline -4.69 -5.28 -5.91 -5.03 
Meprobamate -1.82 -1.36 -1.62 -1.44 
Mercaptopurine -3.09 -1.84 -0.70 -1.66 
Metoclopramide -3.18 -2.99 -2.85 -3.04 
Metronidazole -1.22 -0.585 -1.14 -1.09 
Minoxidil -1.98 -2.97 -2.19 -2.46 
Mitomycin C -2.56 -2.53 -0.12 -2.46 
Mycophenolic acid -4.39 -3.30 -4.99 -3.19 
Nifedipine -4.78 -2.10 -3.71 -2.42 
Nitrofurantoin -3.24 -2.19 -0.98 -2.03 
Nitroglycerin -2.26 -1.19 -2.22 -1.66 
Omeprazole -3.62 -3.21 -3.00 -4.43 
Oxytetracycline -3.09 0.07 -4.04 -3.30 
p-Aminobenzoic acid -1.37 -1.93 -0.65 -1.65 
Papaverine -3.87 -4.43 -4.66 -4.67 
Phenobarbital -2.29 -2.39 -1.90 -2.59 
Phenytoin -3.99 -4.07 -3.20 -3.35 
Progesterone -4.40 -4.35 -5.64 -4.08 
Propofol -3.05 -3.38 -3.82 -3.28 
Propoxyphene -5.01 -4.38 -6.45 -4.14 
Prostaglandin–E2 -2.47 -2.73 -5.22 -3.16 
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Quinine -2.82 -2.11 -4.01 -4.06 
Riboflavin -3.65 -0.43 -2.77 -2.21 
Salicylic acid -1.93 -2.87 -1.53 -2.24 
Sertraline -4.94 -6.59 -6.17 -4.98 
Sulfacetamide -1.23 -0.99 -0.83 -1.64 
Terfenadine -6.69 -6.63 -9.05 -6.39 
Testosterone -4.06 -4.02 -4.89 -3.66 
Theophylline -1.38 -2.09 -0.18 -1.71 
Thiabendazole -3.48 -4.68 -3.21 -3.94 
Tolbutamide -3.46 -2.93 -3.13 -2.93 
Trimethoprim -2.95 -2.22 -6.11 -2.61 
Warfarin -3.89 -3.19 -7.40 -3.61 
Table 3. List of the test data set for evaluating the capability of the models for aqueous 
solubility prediction, the experimental (logSW) and predicted values by equations 4-6 
The solubility value of a drug is affected by pH which is largely depends on whether the 
compound has acid/base ionizable functional groups. Most of the pharmaceutical 
compounds are weak acids or bases which could be dissociated according to the following 
equlibria: 
 
3
2 3: ,
pKa
a
A H O
Acidic Drug HA H O A H O pK
HA
 
             
 2: ,
pKb
b
BH OH
Basic Drug B H O BH OH pK
B
 
             
where HA and B are acidic and basic drugs, respectively, pKa is the acid dissociation 
constant, and pKb is basic dissociation constant. The solubility of a weak acid or base in 
solutions with different pH is calculated by Henderson–Hasselbalch equation: 
  0: log log log 10 1pH pKaTAcidic Drug S S     (7a) 
  0: log log log 10 1pKa pHTBasic Drug S S     (7b) 
where ST and S0 are total and intrinsic solubility, respectively. So for solubility prediction of 
a drug at different pH values we need to have intrinsic solubility and pKa value for the drug 
(Sinko and Martin, 2006). 
However, having a specific pKa value for a compound does not mean it will have complete 
activity in every pH values which is the case for most of the drugs which do not have 
complete activity in aqueous solutions. 
There are some mathematical models for calculation of the solubility and pKa of the 
compounds (Dearden, 2006; Jouyban, 2009; Katritzky et al., 2010). However, complete 
activity will be gained in two conditions: 1- infinite dilution and 2- strong acidic condition 
for basic compounds (or strong basic condition for acidic compounds). 
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3.2 Solubility in organic solvents 
Few models were presented to calculate the solubility of drugs in organic solvents. 
Yalkowsky et al. (1983) calculated the mole fraction solubility of weak electrolytes and non-
electrolytes in n-octanol at 30 C as: 
 log 0.011 0.15OctX mp    (8) 
 log 0.013 0.44OctX mp    (9) 
Dearden and O’Sullivan (1988) proposed the following equation for calculating the molar 
solubility of drugs in cyclohexane ( CycS ): 
 log 0.0423 1.45CycS mp    (10) 
which was tested on the solubility of 12 pharmaceuticals and the mean percentage deviation 
was 85.1 (± 21.6) % (Jouyban, 2009). 
Sepassi and Yalkowsky (2006) proposed another version of equation 8 to compute the molar 
solubility of drugs in octanol as: 
  log 0.01 25 0.5OctS mp     (11) 
The mean percentage value of equation 11 was 147 (± 247) % (Jouyban, 2009). 
The Abraham solvation model provides a more comprehensive solubility prediction method 
for organic solvents (Abraham et al., 2010). The Abraham model written in terms of 
solubility is: 
 log S
W
S
c e E s S a A b B v V
S
              
 (12) 
where SS  and WS  are the solute solubility in the organic solvent and water (in mole/L), 
respectively. In equation 12, the coefficients c, e, s, a, b and v are the model constants (i.e. 
solvent’s coefficients), which depend upon the solvent system under consideration. These 
coefficients were computed by regression analysis of measured log S
W
S
S
   
 values, infinite 
dilution activity coefficients and partition coefficients of various solutes against the 
corresponding solute parameters (Abraham and Acree, 2005). The Abraham solvent 
coefficients (c, e, s, a, b and v) and Abraham solute parameters (E, S, A, B and V) represent 
the extent of all known interactions between solute and solvents in the solution (Stovall et 
al., 2005b). 
3.3 Solubility at different temperatures 
Solubility of a solute in an ideal solution could be mathematically represented by van’t Hoff 
equation: 
 log
a
S b
T
   (13) 
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where a is the slope of the linear plot of lnS against 
1
T
 and b is the intercept. The a term is 
equal to 
2.303
fH
R

 and b is equal to 
2.303
f
m
H
RT

 for ideal solutions in which R is the molar gas 
constant and Tm is the melting point expressed as K. Equation 13 provides good relationship 
in the narrow range of temperature. For ideal solutions, the enthalpy of mixing is zero, 
therefore the enthalpy of solution ( sH ) is equal to the enthalpy of fusion ( fH ). The sH  
is always endothermic for ideal solutions, and the solute solubility will be increased by 
increasing the temperature. The pattern is different for gases, liquids and solids as shown in 
Figure 4 where the solubility of gases decreases with increased temperature. The 
Hildebrand equation is an alternative model and expressed as: 
 log lnS a T b   (14) 
in which a and b are the adjustable parameters. Equations 13 and 14 fail to represent the 
solubility-temperature relationship of most of pharmaceutical compounds in water and 
other pharmaceutically interested solvents especially at a wide temperature range. There are 
some physico-chemical reasons for this deviation from linear relationships, e.g. formation of 
polymorphs or solvate forms of the drug, which was discussed in details by Grant et al. 
(1984). To represent such data, a combined version of the van’t Hoff and Hildebrand 
equations could be used. The equation is: 
 log ln
a
S b T c
T
    (15) 
in which a, b and c are the adjustable parameters calculated by a least square analysis (Grant 
et al., 1984). 
 
Fig. 4. The van’t Hoff plot for gases, liquids and solids 
3.4 Solubility in mixed solvents 
The log-linear model of Yalkowsky is the simplest and famous model to calculate the 
solubility of pharmaceuticals in mixed solvent systems and is expressed by: 
 2 1log logmS S f    (16) 
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where mS  is the solubility of the solute in the mixed solvent system, 2S  denote the aqueous 
solubility of drug,   is the solubilization power of the cosolvent and theoretically is equal 
to 1 2(log( / ))S S  in which 1S  is the solubility in the neat cosolvent (Yalkowsky and 
Roseman, 1981). The general form of the log-linear model for multi-component solvent 
systems could be written as: 
 2log logm i iS S f   (17) 
where i  and if  are the solubilization power and the fractions of cosolvent i (Li, 2001). 
Valvani et al. (1981) reported a linear relationship between   and logarithm of drug’s 
partition coefficient ( log P ) which is a key relationship and could improve the prediction 
capability of the log-linear model. The relationship was expressed as: 
 logM P N     (18) 
where M and N are the cosolvent constants and are not dependent on the solute’s nature. 
The numerical values of M and N were reported for most of the common cosolvents earlier 
(Li and Yalkowsky, 1998) and listed in Table 4. This version of the log-linear model could be 
considered as a predictive model and provided the simplest solubility estimation method 
and requires the aqueous solubility of the drug and its experimental/calculated logP value 
as input data. The log-linear model was developed to predict the solubility of drugs at room 
temperature (22 – 27 C) however the solubility at other temperatures are also required in 
the pharmaceutical industry. 
 
Solvent system M N 
Acetone - water 1.14 -0.10 
Acetonitrile – water 1.16 -0.49 
Butylamine – water 0.64 1.86 
Dimethylacetamide – water 0.96 0.75 
Dimethylformamide – water 0.83 0.92 
Dimethylsulphoxide – water 0.79 0.95 
Dioxane – water 1.08 0.40 
Ethanol – water 0.93 0.40 
Ethylene glycol – water 0.68 0.37 
Glycerol – water 0.35 0.26 
Methanol – water 0.89 0.36 
Polyethylene glycol 400 – water 0.74 1.26 
1-Propanol – water 1.09 0.01 
2-Propanol – water 1.11 -0.50 
Propylene glycol - water 0.77 0.58 
Table 4. Updated Table from (Li and Yalkowsky, 1998; Millard et al., 2002.) 
The Jouyban-Acree model was adopted from the combined nearly ideal binary 
solvent/Redlich-Kister equation proposed by Prof. Acree (1992) which was derived from a 
thermodynamic mixing model that includes contributions from both two-body and three-
body interactions (Hwang et al., 1991). The model was presented for solubility calculations 
in binary solvents at a fixed temperature and expressed as: 
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  21 1 2 2 1 2 1 2
0
log log log
i
m i
i
S f S f S f f A f f

     (19) 
where iA  stands for the model constants. The iA  values are calculated by regressing 
 1 1 2 2log log logmS f S f S   against 1 2f f ,  1 2 1 2f f f f  and  21 2 1 2f f f f  by a no 
intercept least squares analysis (Jouyban-Gharamaleki and Hanaee, 1997). The applicability 
of the model was extended to other physico-chemical properties in mixed solvents at 
various temperatures as: 
  21 2, 1 1, 2 2, 1 2
0
log log log
i
m T T T i
i
f f
S f S f S J f f
T 
     (20) 
where ,m TS , 1,TS  and 2,TS  are the solubility in solvent mixture, mono-solvents 1 and 2 at 
temperature T (K) and iJ  is the model constants. The main limitations of the Jouyban-Acree 
model for predicting drug solubilities in solvent mixtures are: a) it requires two data points 
of solubilities in mono-solvent systems, and b) numerical values of the model constants. To 
overcome the first limitation, the solubility prediction methods in mono-solvent system 
should be improved. To address the second limitation, the following solutions were 
examined during last couple of years:  
i. the iJ  terms are obtained using solubility of structurally related drugs in a given mixed 
solvent system, and then predict the un-measured solubility of the related drugs where 
the expected mean percentage deviation was ~ 17 % (Jouyban-Gharamaleki et al., 1998).  
ii.  the model constants could be calculated using a minimum number of experimental 
data points, i.e. three data points, and then predict the solubilities at the rest of solvent 
compositions where the expected prediction mean percentage deviation was < 15 % 
(Jouyban-Gharamaleki et al., 2001).  
iii.  the trained versions of the Jouyban-Acree models could be employed for solubility 
prediction of drugs in the aqueous mixtures of a number of organic solvents were 
reported. Using this version of the model, only the solubility data in mono-solvents are 
required. Table 5 listed the numerical values of the Jouyban-Acree model constants for 
the 5 cosolvents studied.  
 
 
Solvent system J0 J1 J2 Prediction % error 
Dioxane - water 958.44 509.45 867.44 27 
Ethanol – water 724.21 485.17 194.41 48 
Polyethylene glycol 400 – water 394.82 -355.28 388.89 40 
Propylene glycol - water 37.03 319.49 - 24 
Ethanol – ethyl acetate 382.987 125.663 214.579 13 
Table 5. The constants of the Jouyban-Acree model for a number of solvent systems, data 
taken from (Jouyban and Acree, 2007; Jouyban, 2008) 
iv. in the trained versions of the Jouyban-Acree model, we assumed the extent of the 
solute-solvent interactions are the same, however, it is not the case since various solutes 
possess different functional groups leading to various extent of the solute-solvent 
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interactions. To cover this point, the deviated solubilities from the trained versions of 
the Jouyban-Acree model were correlated using available solubility data sets in ethanol 
– water and dioxane – water mixtures at various temperatures and the following 
equations are obtained:  
 
 
   
 
, 1 1, 2 2,
1 2
1 2 1 2
2
1 2 1 2
log log log
558.45 358.60 22.01 352.97 130.48 297.10
45.67 165.77 321.55 479.48 409.51 827.63
493.81 341.32 866.22 36.17 1
m T T TS f S f S
f f
E S A B V
T
f f f f
E S A B V
T
f f f f
E S A
T
 
        
         
         
 73.41 555.48B V
 (21) 
and 
 
 
   
 
, 1 1, 2 2,
1 2
1 2 1 2
2
1 2 1 2
log log log
648.01 404.99 428.69 340.99 59.03 56.94
135.95 41.11 192.19 237.81 363.87 310.30
1102.49 667.02 2070.16 421.15
m T T TS f S f S
f f
E S A B V
T
f f f f
E S A B V
T
f f f f
E S
T
 
        
          
        
 924.73 271.54A B V 
 (22) 
The mean percentage deviation values for ethanol and dioxane were 34 and 22 %, 
respectively (Jouyban et al., 2009).  
v. a generalized version of the Jouyban-Acree model was proposed using its combination 
with the Abraham solvation parameters where the model constants of the Jouyban-
Acree model were correlated with the functions of the Abraham solvent coefficients and 
the solute parameters as: 
The mean percentage deviation of this model was 42 % for 152 data sets which was 
significantly less than that of the log-linear model (78 %). Figure 5 shows the relative 
frequency of the individual percentage deviations of the predicted solubilities using 
equations 23 and 16 (log-linear) in which the error distribution of equation 23 is better 
than that of the log-linear model. It should be noted that the Jouyban-Acree model 
requires two experimental data points, i.e. 1,TS  and 2,TS , whereas the log-linear model 
needs just aqueous solubility of the drug as input data. The main advantage of equation 
23 is that it could be used to predict the solubility in mixed solvents where the Abraham 
solvent parameters (i.e. c, e, s, a, b and v) are available. Table 6 listed these parameters for 
a number of more common solvents in the pharmaceutical industry. Unfortunately these 
parameters are not available for a number of more common pharmaceutical cosolvents, 
such as propylene glycol and polyethylene glycols, and this is a disadvantage for this 
model. 
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1 2 1 2 1 2
1 2
2 2 2
1 2 1 2 1 2
2
1 2
1 2 1 2
log log log
1639.07 561.01 1344.81 18.22
3.65 0.86 4.40
1054.03 1043.54
m T T TS f S f S
c c E e e S s sf f
T A a a B b b V v v
c cf f f f
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 
                                        
        
   
     
       
 
2 2
1 2 1 2
2 2 2
1 2 1 2 1 2
2 2 2
2
1 2 1 2 1 2
1 2 1 2
2
1 2 1
359.47 1.20
30.26 2.66 0.16
2895.07 1913.07 901.29 10.87
24.62 9.79
E e e S s s
A a a B b b V v v
c c E e e S s sf f f f
T A a a B b
                               
                              2 22 1 224.38b V v v
             
 (23) 
In addition to the above discussed models to predict the solubility of drugs in solvent 
mixtures, there are some models derived from molecular thermodynamic approaches. These 
models require relatively complex computations and did not attract more attention in the 
pharmaceutical area. These models provide comparable prediction accuracies with the 
above discussed models. As an example, the prediction error of a method based on 
statistical mechanical fluctuation solution theory varied 0.3-58 % (Ellegaard et al., 2010) 
whereas the corresponding value for the common models in the pharmaceutical area varied 
between 8 to 19 % (Jouyban-Gharamaleki et al., 1999).  
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Fig. 5. The relative frequencies of the predicted solubilities in binary solvent mixtures using 
Jouyban-Acree and log-linear models 
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Solvent c e s a b v 
Acetone 0.335 0.349 -0.231 -0.411 -4.793 3.963 
Acetonitrile 0.413 0.077 0.326 -1.566 -4.391 3.364 
Dimethyl formamide -0.438 -0.099 0.670 0.878 -4.970 4.552 
Dioxane 0.098 0.350 -0.083 -0.556 -4.826 4.172 
Ethanol 0.208 0.409 -0.959 0.186 -3.645 3.928 
Ethylene glycol 0.243 0.695 -0.670 0.726 -2.399 2.670 
Methanol 0.329 0.299 -0.671 0.080 -3.389 3.512 
2-Propanol 0.063 0.320 -1.024 0.445 -3.824 4.067 
Water -0.994 0.577 2.549 3.813 4.841 -0.869 
Table 6. The Abraham solvent parameters of a number of common solvents (data taken from 
Stovall et al., 2005a; 2005b) 
3.5 Solubility in the presence of surfactants 
Equation 24 is one of the equations used for the solubility calculation in presence of 
surfactant (Rangel-Yagui et al., 2005): 
 
 
 tanT WSurfac t
S S
C cmc
    (24) 
where χ is the ratio of the concentration of the drug in micelles to the concentration of the 
micellar surfactant molecules, ST is the total drug solubility in the solution, SW is the 
aqueous solubility of the drug, CSurfactant is the molar concentration of the surfactant in the 
solution, and cmc is the critical micelle concentration. Another equation is (Rangel-Yagui et 
al., 2005): 
 T W
W
S S
K
S
  (25) 
where K is the micelle-water partition coefficient of the drug. 
However, these equations require at least two other experimental data as input for total 
solubility prediction of the drug in micellar solutions.  
Abraham et al. (1995) have proposed two models for prediction of K for different solutes in 
the presence of sodium dodecylsulfate (SDS) as: 
 
log 1.201 0.542 0.400 0.133 1.580 2.793
0.9849 , 132 , standard deviation 0.171
xK E S A B V
R N
     
    (26) 
and 
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log 1.129 0.504log 1.216
0.9755 , 132 , standard deviation 0.215
xK P V
R N
  
    (27) 
where Kx is the definition of K of equation 25 in mole fraction unit (Abraham et al., 1995). 
Ghasemi and coworkers have developed a MLR model for micellar solubility prediction in 
the presence of SDS for a diverse set of compounds: 
 
2
log 0.638 0.001 0.384 0.112 0.570 log 0.001Re
0.9679 , 62 , 0.124
S bK E MR LUMO C P pE
R N RMSEP
      
    (28) 
where KS is the micellar solubility, Eb is bending energy, MR is molar refractivity, LUMO is 
the lowest unoccupied molecular orbital, ClogP is logarithm of calculated partition 
coefficient and RepE is the repulsion energy (Ghasemi et al., 2008). In other work, they have 
proposed a QSPR model for micellar solubility prediction for a diverse set of compounds in 
presence of cetyltrimethylammonium bromide (CTAB) as: 
 
2
log 1.1522 0.0070 0.8089log 0.1262
0.9624 , 40 , 0.169
SK MP P DPLL
R N RMSEP
    
    (29) 
where MP is melting point of the solute, and DPLL is the dipole length of the solute 
(Ghasemi et al., 2009). 
However, as mentioned above, at least intrinsic solubility is required for total solubility 
prediction in the presence of a surfactant and they cannot be used as ab initio QSPR models 
for solubility prediction. 
3.6 Solubility in the presence of complexing agents 
In most of the cases, by adding complexing agents (e.g. cyclodextrins) to the solution, the 
solubility of a specific ligand (i.e. drug) is enhanced. But this enhancement could have 
different types as illustrated in Figure 6. 
As has been seen, different kinds of drugs show different behaviours. But except for one 
condition, in the smaller amounts of complexing agent, the solubility changes are the same 
for other types. This common part of the curves is considered as a straight line with a slope 
of: 
  
   
1:1 0
1:1 0
1:1
1
.
K S
Slope
K S
Host Ligand
K
Host Ligand
 
 
 (30) 
where K1:1 is the complex formation coefficient, [Host.Ligand] is the concentration of the 
formed complex between drug and complexing agent, [Host] is the concentration of the 
complexing agent, and [Ligand] is the concentration of the drug (Sinko and Martin, 2006; 
Brewster and Loftsson, 2007). To correlate solubility value in presence of a complexing agent 
in this part of the solubility curve, one can use the following equation: 
 0
Complex
HostTotalS S Slope C    (31) 
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where ComplexTotalS is the total solubility amount in the presence of a complexing agent, S0 is the 
intrinsic solubility, Slope is the slope of the first part of solubility curve versus complexing 
agent concentrations, and CHost is the concentration of the complexing agent (Sinko and 
Martin, 2006; Brewster and Loftsson, 2007). 
 
 
Fig. 6. Possible different solubility behaviours in the presence of complexing agent. 
Again, like the pH and surfactant effects, one must have intrinsic solubility and Slope (or 
K1:1) for solubility prediction in presence of complexing agents. However some QSPR 
models have been developed for prediction of Slope (or K1:1). But most of them only 
considered the effect of complexing agent on the solubility enhancement (i.e. Slope). Demian 
(2000) has proposed equation 32 for the correlation of the Slope of the above mentioned 
equation for aromatics and terpenes with hydroxypropyl-ǃ-cyclodextrin: 
 
2.86 0.11 0.34 log
0.788 , 19 , standard error 0.336
Slope SterimolL P
R N
    
    (32) 
where SterimolL is a steric parameter which is calculated by ChemOffice software (Demian, 
2000). Choi et al. (2006) have developed a QSPR model for the correlation of the Slope for AL 
type solubility curves between drugs and ǂ/ǃ/Ǆ-cyclodextrines as following: 
 
_ _
2
0.012 0.102 0.328 0.305
0.913 , 63 , standard error 0.028
h g np h g np g gSlope E E E
R N
      
    (33) 
where Eh-g is the interaction energy between host and guest, Enp_h-g is the difference between 
nonpolar components of free energy of solvation of the host–guest complex and those of 
individual host and guest molecules, Enp_g-g is the difference between nonpolar components 
of free energy of solvation of the guest–guest dimer and those of individual guest molecule 
(Choi et al., 2006). These energy values are calculated after a Monte Carlo docking 
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simulation between each drug and related complexing agent. Trapani et al. (2005) have 
developed a QSPR model for the correlation of the ratio of the total versus intrinsic 
solubilities of 25 drugs in the presence of 2-hydroxypropyl-ǃ-cyclodextrin as following: 
 0
2 2
log 3.766 0.182 0.150 log 0.00683 0.0844
0.793 , 25 , 0.711
Complex
Total
tot
S
CMR C P TPSA
S
R N Q
    
  
 (34) 
and 
 0
2 2
log 1.827 0.00508 0.0122 0.179 log 0.00547
0.763 , 25 , 0.605
Complex
TotalS MW MV C P TPSA
S
R N Q
    
  
 (35) 
where CMR is calculated molecular refractivity, TPSA is total polar surface area, δtot total 
solubility parameter, MW is molecular weight, and MV is molecular volume. Equation 34 
was derived using a MLR method and equation 35 was derived using a PLS method 
(Trapani et al., 2005). 
However, as mentioned earlier, none of these models can be applied directly for solubility 
prediction in the presence of complexing agents and intrinsic solubility is required for all of 
them. 
3.7 Available software 
There is almost a large number of software for solubility prediction. A thorough review of 
these software was provided in an article (Jouyban et al., 2008). In this chapter, more useful 
solubility prediction applications and those which are newly developed or related with drug 
design and development is discussed. 
ACD/Solubility DB predicts aqueous solubility at different pH with an accuracy of average 
error of 0.47±0.67 (in decimal logarithm) for solubility prediction of 1125 compounds 
(ACD/Labs). 
ACD/DMSO Solubility predicts whether a compound is soluble (a result of 1) or insoluble 
(a result of 0) in DMSO. Using a hybrid model of logistic regression with PLS method, its 
predictive model was trained with solubility related physicochemical parameters, and 
considering the effects of charged groups, atom chains, and ring scaffolds. It provides 30% 
high reliability, 70% moderate reliability and <1% low reliability in prediction, with an 
overall accuracy of 82% in correct prediction (Japertas et al.). 
Simulations plus’ ADMET predictor™, predicts aqueous solubility using 2D and 3D 
descriptors as input data with average error of 0.432 and 0.423 in logarithm scale for 2817 
and 711 number of compounds in train and test sets, respectively (ADMET Predictor™). It 
can also predict the solubility in biorelevant medium of the fasted state simulated gastric 
fluid (FaSSGF), the fasted state simulated intestinal fluid (FaSSIF), and the fed state 
simulated intestinal fluid (FeSSIF). Its average errors in logarithm scale for FaSSGF are 0.510 
and 0.470 for 137 and 20 compounds, respectively. Its average errors in logarithm scale for 
FaSSIF are 0.469 and 0.417 for 141 and 16 compounds, respectively. Its average errors in 
logarithm scale for FeSSIF are 0.424 and 0.409 for 136 and 21 compounds, respectively. These 
predictive tools are designed using 2D descriptors as inputs and ADMET Modeler's ANNE 
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methodology for modelling (ADMET Predictor™). This package also can predict possibility 
of supersaturation in water. It calculates ratio of kinetic solubility versus intrinsic solubility 
and if the result is higher than 1.3, then the answer to possibility of supersaturation is true. It 
classified 95 and 23 out of 97 and 24 compounds correctly as train and test sets (ADMET 
Predictor™). 
Finally, Solvomix is a recently developed free software available via Handbook of Solubility 
Data for Pharmaceuticals as a tool for prediction of solubility in monosolvents and mixtures 
of solvents. It uses GSE and Abraham models for the prediction of solubility in 
monosolvents and trained versions of log-linear model of Yalkowsky and Jouyban-Acree 
model for solubility prediction in mixtures of solvents (Jouyban, 2009).  
4. Conclusion 
Although preparation of a drug solution is a simple procedure, the associated problems are 
still a challenging subject in the pharmaceutical area. Brief review of its importance, various 
experimental and computational methods to determine the solubility and a number of more 
common methods to alter the solubility are discussed in this chapter. A comprehensive 
compilation of aqueous solubility data of chemical/pharmaceutical compounds is available 
from a reference work of Yalkowsky et al. 2010. The solubility data of pharmaceuticals in 
organic mono-solvents and also aqueous and non-aqueous solvent mixtures are compiled in 
a recent work (Jouyban, 2009). 
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